Police raid French HQ of Merck KGaA over thyroid drug scandal
pharmafile | October 4, 2017 | News story | Manufacturing and Production, Research and Development, Sales and Marketing | Levothyrox, Merck KGaA, hyperthyroidism, pharma, pharmaceuticals
Police have raided the French headquarters of German drug manufacturer Merck KGaA over a scandal concerning its thyroid treatment Levothyrox, whereby more than 9,000 patients allege that the drug has caused a range of detrimental side-effects.
Merck updated the formula used in Levothyrox back in March this year at the request of French regulator ANSM, and the country was the first to market the new version of the drug. The company removed lactose from the product to improve tolerability, replacing it with citric acid and mannitol, a type of sugar alcohol. Since the new version became available, patients have reported cases of hair loss, weight gain, palpitations and hair loss as a result of taking the drug.
Levothyrox works to treat hyperthyroidism by substituting for low levels of the thyroxine hormone. Around three million people in France use the drug, and around 80% of them are female.
The investigation as carried out by police from the public regulatory agency OCLAESP on the basis of 61 legal complaints, including alleged involuntary bodily harm, misleading of customers and endangering lives. The investigation was originally launched in September last year by a Marseille prosecutor and centred on whether or not Merck had mislead patients with the change in formula.
Merck said that the raid was “expected” and that it is “ready to help investigators with their work.”
In the meantime, limited quantities of the drug’s old formulation were made available in France following the raid. It will remain available in addition to the new version until other treatments are made available.
Matt Fellows
Related Content
Exscientia enters AI drug discovery collaboration with Merck KGaA
Exscientia has announced a new collaboration with Merck KGaA, Darmstadt, Germany, with a focus on …
FDA approves IMIDEX’s AI-powered device VisiRad XR
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …
Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo
On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …
